Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Merck Kgaa Dm 5 (MKGAF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 14,517,995
  • Shares Outstanding, K 129,240
  • Annual Sales, $ 16,626 M
  • Annual Income, $ 1,803 M
  • 36-Month Beta 0.66
  • Price/Sales 0.89
  • Price/Cash Flow 2.86
  • Price/Book 0.94
  • Price/Earnings ttm 15.81
  • Earnings Per Share ttm 5.36
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/10/17
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
110.8800 +1.31%
on 10/17/17
115.8000 -2.99%
on 09/26/17
-2.9064 (-2.52%)
since 09/12/17
3-Month
106.3000 +5.68%
on 08/18/17
116.0000 -3.16%
on 07/21/17
-4.1564 (-3.57%)
since 07/17/17
52-Week
97.5600 +15.14%
on 12/08/16
124.4000 -9.70%
on 05/12/17
+5.9936 (+5.64%)
since 10/17/16

Most Recent Stories

More News
Biogen & 6 Other Multiple Sclerosis Drug Stocks in Focus: Here's Why

Late last week, Biogen (BIIB) and six other pharma and biotech stocks were in the news due to the pricing of their multiple sclerosis ("MS") drugs.

BAYRY : 35.0600 (-0.65%)
NVS : 86.34 (-0.03%)
TEVA : 14.74 (+0.20%)
RHHBY : 31.4500 (+0.87%)
MKGAF : 112.3336 (-0.07%)
SNY : 49.59 (-0.08%)
BIIB : 344.47 (+2.62%)
Merck KGaA (MKGAF) Q2 Earnings Up Y/Y

Merck KGaA (MKGAF) reports second-quarter results with earnings rising year-over-year and sales registering organic growth.

MKGAF : 112.3336 (-0.07%)
What's in the Cards for Merck KGaA (MKGAF) in Q2 Earnings?

Merck KGaA???s (MKGAF) Life Science segment is expected to perform well following the approval of Bavencio.

ZTS : 65.81 (+0.15%)
CLVS : 81.32 (-3.85%)
PFE : 36.20 (+0.61%)
MKGAF : 112.3336 (-0.07%)
Merck KGaA (MKGAF) Q1 Earnings Fall Y/Y, Revenues Increase

Merck KGaA (MKGAF) reported first-quarter 2017 earnings of $1.28 per American Depositary Share, 14.7% lower than the year-ago figure of $1.50.

RHHBY : 31.4500 (+0.87%)
PFE : 36.20 (+0.61%)
MKGAF : 112.3336 (-0.07%)
BMY : 64.18 (+0.83%)
Merck KGaA (MKGAF) Q1 Earnings Down Y/Y, 2017 View Updated

The company???s first-quarter 2017 earnings per American Depositary Receipt (ADR) came in at $1.28, compared to the year-ago figure of $1.50

MKGAF : 112.3336 (-0.07%)
What's in Store for Merck KGaA (MKGAF) in Q1 Earnings?

Merck KGaA (MKGAF) is scheduled to report first-quarter 2017 earnings results on May 18.

AZN : 34.78 (+0.38%)
EDIT : 23.20 (+1.80%)
PFE : 36.20 (+0.61%)
MKGAF : 112.3336 (-0.07%)
What's in Store for Merck KGaA (MKGAF) in Q4 Earnings?

Merck KGaA (MKGAF) is scheduled to report fourth-quarter 2016 earnings results on Mar 9.

BMRN : 93.54 (-1.18%)
PFE : 36.20 (+0.61%)
MKGAF : 112.3336 (-0.07%)
BMY : 64.18 (+0.83%)
Is BioMarin (BMRN) Well Poised for Growth in 2017?

We issued an updated research report on BioMarin Pharmaceutical Inc. (BMRN) on Jan 25.

ENDP : 7.64 (+0.26%)
SRPT : 51.72 (+1.95%)
BMRN : 93.54 (-1.18%)
MKGAF : 112.3336 (-0.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More

Support & Resistance

2nd Resistance Point 113.7505
1st Resistance Point 113.0421
Last Price 112.3336
1st Support Level 111.2526
2nd Support Level 110.1715

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart